Alpha Biopharma, a China-based developer of innovative drugs, announced on Sunday that the company's New Drug Application (NDA) for Zorifertinib, a next-generation EGFR-TKI, has been accepted by the Centre for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), China's drug regulator.
Zorifertinib is intended to treat advanced EGFR-mutated non-small cell lung cancer (NSCLC) subjects with central nervous system (CNS) metastases. It is the first EGFR-TKI to be tested in a prospective, controlled registration clinical study for this difficult-to-treat patient population. If the product receives approval, then it will bring a much-needed new treatment option for these subjects.
The EVEREST study was a multinational, multicentre, randomised, open-label, controlled phase II/III clinical trial designed to evaluate the efficacy and safety of Zorifertinib as a first-line treatment for advanced EGFR-mutated NSCLC patients with CNS metastases. The study was carried out in 55 study sites located in the Chinese mainland, Taiwan, South Korea, and Singapore, with a total enrolment of 492 patients. The last patient last visit (LPLV) of the EVEREST study was completed in the third quarter of 2022. Results from the EVEREST study demonstrated that Zorifertinib effectively reduced the risk of disease progression and patient deaths in the target patient population and showed significant efficacy in treating metastatic lesions in the CNS. In addition, Zorifertinib's safety profile is comparable to other approved EGFR-TKI's. The primary resistance mutation at the time of disease progression is the EGFR T790M mutation.
Professor Yilong Wu, president of the Chinese Thoracic Oncology Group (CTONG) and the leading principal investigator (PI) of the EVEREST study, said, 'Clinical results from this high-quality, controlled study demonstrated that Zorifertinib provided consistent and statistically significant benefits to EGFR-mutated NSCLC patients with different levels of CNS metastasis. It could provide a much-needed new treatment option for these difficult-to-treat patients. The development of Zorifertinib represents a great example of a patient-centric, targeted precision approach to address unmet medical needs.'
SCG releases SCG101 late-breaking clinical data in HBV-related hepatocellular carcinoma
Genprex signs new research agreement with University of Pittsburgh to advance diabetes gene therapy
AstraZeneca and Daiichi Sankyo's Enhertu shows strong results in early-stage breast cancer trial
Adcentrx's ADRX-0706 granted US FDA Fast Track designation to treat advanced cervical cancer
Ajinomoto and RIBOMIC announce successful extension of nucleic acid aptamer pharmacokinetics
AstraZeneca secures EU approval for Calquence combo as first-line treatment in mantle cell lymphoma
Odylia Therapeutics undertakes gene replacement therapy project for NPHP1 retinal dystrophy
Phanes Therapeutics doses first patient in peluntamig-atezolizumab combination clinical study
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg
Nutshell Therapeutics' NTS071 p53 allosteric reactivator cleared for US clinical trial